Stay updated on BCD-020 Safety & Efficacy in Indolent NHL Clinical Trial
Sign up to get notified when there's something new on the BCD-020 Safety & Efficacy in Indolent NHL Clinical Trial page.

Latest updates to the BCD-020 Safety & Efficacy in Indolent NHL Clinical Trial page
- Check3 days agoChange DetectedA new metadata revision tag 'Revision: v3.3.4' was added and the previous tag 'Revision: v3.3.3' was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe footer now shows Revision: v3.3.3, and the HHS Vulnerability Disclosure link along with Revision: v3.3.2 were removed.SummaryDifference0.1%

- Check54 days agoChange DetectedRevision: v3.3.2 was added and Revision: v3.2.0 was removed.SummaryDifference0.0%

- Check61 days agoChange DetectedRemoved the government funding/operating-status notice from the page.SummaryDifference0.3%

- Check82 days agoChange DetectedAdded Cali, Colombia as a study site and removed Santiago de Cali, Colombia from the locations. This updates the study's site list and may affect participant access and logistics.SummaryDifference0.4%

- Check104 days agoChange DetectedMajor update: adds an operating-status notice and updates version to v3.2.0; removes the Follicular lymphoma resource (from GRDIC).SummaryDifference4%

Stay in the know with updates to BCD-020 Safety & Efficacy in Indolent NHL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BCD-020 Safety & Efficacy in Indolent NHL Clinical Trial page.